A Case of a Patient with Umbilical Metastasis of Recurrent Cancer (Sister Mary Joseph's Nodule, SMJN) Who has Survived for a Long Time under Immunomodulatory Supplement Therapy

Tomonori KAWAI
Shinkurashiki icho komon geka*

Summary

A 64-year-old female patient with umbilical metastasis of recurrent colorectal cancer (SMJN) was treated by complementary medicine using the rice bran arabinoxylan derivative1-2, a food component of BRM activity, in addition to chemotherapy, in order to maintain QOL and prolong survival. Although the umbilical metastasis tends to grow, the patient is in a good nutritional condition and has survived for more than two years from diagnosis. SMJN is a distant metastasis, and even with the first occurrence, radical treatment may not be possible in most cases. This case suggests that the maintenance of the QOL and physiological function may lead to prolongation of life even in patients with terminal cancer with extremely poor prognosis. This case also presents the benefits of supplementary therapy using functional foods.

Key words: colorectal cancer, immunotherapy, rice bran arabinoxylan derivative

Introduction

Umbilical metastasis of malignant tumors in visceral organs is known as Sister Mary Joseph's Nodule (SMJN). This is named after Sister Mary Joseph, a nurse working in an operating room, who noticed that gastric-cancer patients with umbilical metastasis had a poor prognosis3. The primary lesion is in the stomach, pancreas, ovary, or large intestine, but the metastatic route is controversial. Our search showed that there are 11 reports on SMJN originating from colorectal cancer (Table 1). We report here the case of a patient with SMJN from the ascending colon who has survived for a long time under chemotherapy and supplement therapy with the immunomodulatory functional food, rice bran arabinoxylan derivative (BioBran).
<table>
<thead>
<tr>
<th>No.</th>
<th>Name</th>
<th>Age</th>
<th>Sex</th>
<th>Description and size of tumor</th>
<th>Treatment and others</th>
<th>Primary lesion</th>
<th>Complications</th>
<th>Type of cancer cells</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tameshi Matsubara</td>
<td>62</td>
<td>Male</td>
<td>2 × 1.5 cm Uneven, elastic hard, reddish brown</td>
<td>New patient</td>
<td>Sigmoid colon</td>
<td>Intestinal obstruction 2 weeks after examination</td>
<td>Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Shojiro Moriyasu</td>
<td>56</td>
<td>Female</td>
<td>New patient</td>
<td>Cecum</td>
<td></td>
<td></td>
<td>Cystic papillary adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Ninako Nakayama</td>
<td>58</td>
<td>Female</td>
<td>Soybean sized, red, hard tumor</td>
<td>Numerous metastatic foci in the greater omentum and small intestine Confirmatory operation</td>
<td>Cecum</td>
<td></td>
<td>Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Keiko Oku</td>
<td>58</td>
<td>Male</td>
<td>5 × 4 cm Red and cartilage-hard</td>
<td>New patient 5FU (250 mg/day) and Picibanol (0.1 KE/day) Removal of a tumor on the abdominal wall skin</td>
<td>Ascending colon</td>
<td>Liver metastasis, pulmonary edema</td>
<td>Adenocarcinoma</td>
<td>Died after 11 months</td>
</tr>
<tr>
<td>5</td>
<td>Yoshimori Mori</td>
<td>45</td>
<td>Female</td>
<td>0.9 × 1.1 cm Milk-white to light yellow Hard, like a plate of a few centimeters around the navel</td>
<td>First patient Krestin (3 g/day)</td>
<td>Ileoceleal junction</td>
<td>Liver metastasis, pulmonary edema</td>
<td>Adenocarcinoma papillotublar</td>
<td>Died of hepatic coma pneumonia after 10 months</td>
</tr>
<tr>
<td>6</td>
<td>Yutichiro Koizumi</td>
<td>56</td>
<td>Female</td>
<td>Hemorrhagic umbilical tumor (the size of index finger's nail)</td>
<td>New patient Removal of the primary lesion</td>
<td>Sigmoid colon</td>
<td></td>
<td>Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Kazuo Sasaki</td>
<td>64</td>
<td>Male</td>
<td>Finger-sized, elastic hard, hemispherical, red node</td>
<td>New patient Confirmatory operation</td>
<td>Transverse colon</td>
<td></td>
<td>Adenocarcinoma (Moderately differentiated)</td>
<td>Died of pneumonia and renal failure after 2 weeks</td>
</tr>
<tr>
<td>8</td>
<td>Masashi Kanazawa</td>
<td>23</td>
<td>Female</td>
<td>Red/renal enlarged nodular mass</td>
<td>Old patient 5FU (3300 mg/W Umbilical resection</td>
<td>Transverse colon</td>
<td>Ovarian and peritoneal metastases</td>
<td>Signetring cell + mucinous carcinoma</td>
<td>7 months</td>
</tr>
<tr>
<td>9</td>
<td>Yoshihumi Kajimoto</td>
<td>67</td>
<td>Female</td>
<td>New patient Tumor removal</td>
<td>New patient</td>
<td>Transverse colon</td>
<td>Intestinal obstruction</td>
<td>Adenocarcinoma (Moderately differentiated)</td>
<td>3 months</td>
</tr>
<tr>
<td>10</td>
<td>Junichi Mizushima et al.</td>
<td>62</td>
<td>Female</td>
<td>3 × 1.4 cm Bone-like hard, subcutaneous tumor</td>
<td>New patient Tegafur 600 mg/day</td>
<td>Sigmoid colon</td>
<td>Metastatic liver tumor</td>
<td>Adenocarcinoma (Moderately differentiated)</td>
<td>2 months</td>
</tr>
<tr>
<td>11</td>
<td>Eiji Meguro et al.</td>
<td>66</td>
<td>Male</td>
<td>3 × 3 cm New patient Umbilical tumor removal</td>
<td>New patient</td>
<td>Sigmoid colon</td>
<td>Peritoneal metastasis Cachexia</td>
<td>Adenocarcinoma</td>
<td>20 days</td>
</tr>
<tr>
<td>12</td>
<td>Tomonori Kawai</td>
<td>64</td>
<td>Female</td>
<td>3 × 3.7 cm Bone-like hard, reddish-brown tumor</td>
<td>Old patient Immunotherapy, 5FU, 5-Lucovorin, and Toptecin</td>
<td>Ascending colon</td>
<td>Peritoneal metastasis</td>
<td>Adenocarcinoma (Well differentiated)</td>
<td>Surviving for 2 years or more, alive</td>
</tr>
</tbody>
</table>
1. Case presentation

Patient: Female aged 64

Main complaint: Umbilical tumor

Family history: (−)

Medical history: She was diagnosed as having colorectal cancer in April 2000, and underwent a resection of the ascending colon. Effusion appeared in January 2001, and an umbilical lump was found. She received a diagnosis of recurrent cancer, peritoneal dissemination, and umbilical metastasis, and was told that surgery was impossible and that her remaining life expectancy was a few months. She visited our hospital for immunotherapy on January 29, 2002.

Present disease: A 3.0 × 3.9 cm elliptical pink tumor of tooth-like hardness was felt in the navel region, which formed a 7.0 × 5.0 cm unclearly defined mass of the same hardness deep in the abdominal cavity (Figure 1).

Test results at admission

WBC: 5900/mm³
RBC: 4,650,000/mm³
Platelet: 22.7/mm³
CEA: 6.1 ng/ml
NK cell activity: 41% (normal 18-40)
AST/ALT: 17/14
Abdominal CT (Figure 2)
Pathological tissue (Figure 3)

The peripheral blood and immunity were normal, but the tumor marker CEA was at a high level of 6.1 ng/ml.
2. Treatment and clinical course

Table 2 shows the content of treatment and clinical course.

The upper section shows changes over time in CEA, WBC count, RBC count, and NK cell activity. The middle section shows the content of treatment, and the lower indicates the tumor size.

1) January 2002

She rejected administration of anticancer drugs for fear of adverse reactions, and thus immunotherapy only was prescribed. BioBran was taken at 3.0 g/day. The CEA was 6.5 ng/ml and the NK cell activity was 41%. The size of the umbilical tumor was $3.0 \times 3.9$ cm, and the intraperitoneal mass was $7.0 \times 5.0$ cm (Figure 2).

She had a good appetite and defecation/flatus once a day, being in good condition. She walked into the consulting room.

2) February 9, 2002

The NK cell activity increased to 54% after 1 month of BioBran ingestion.

The CEA decreased slightly to 6.1 ng/ml. She reported that, "The umbilical tumor is unchanged, but the intraperitoneal mass is a little reduced."

3) March 15, 2002

The CEA further decreased to 5.6 ng/ml, and the abdominal tumor was unchanged. BioBran was given for 6 months.

4) July 2002

The NK cell activity increased to 55%, but the CEA also increased to 12.6 ng/ml.

The umbilical/intraperitoneal mass slightly increased to $5.0 \times 6.0/10.0 \times 12.0$ cm. She had a good appetite and defecation/flatus.

5) December 2002

The umbilical/intraperitoneal mass was $5.0 \times 6.0/10.0 \times 12.0$ cm. The CEA increased to 24 ng/ml. She had a good appetite and defecation/flatus, but reported, "My stomach is heavy." Her walking condition was good.
6) April 2003

There was no major change from early 2003, but CEA gradually increased to 46.8 ng/ml.

A left inguinal lymph node metastasis was noted. A metastasis of 1.2 × 1.2 cm occurred on the left skin and was removed. The umbilical/intraperitoneal tumor increased to 7.0 × 8.0/29.0 × 24.0 cm, and the dose of BioBran was increased to 6 g/day. The umbilical tumor discharged a large volume of effusion and she reported, "It is a big problem to keep changing the gauze." However, she traveled occasionally, together with her daughter.

7) May 2003

CEA decreased to 38.6 ng/ml. General condition was good. No large change. BioBran was taken for a total of 1 year and 5 months.

8) July 2003

Since the umbilical/intraperitoneal tumor increased to 9.0 × 11.0/30.0 × 25.0 cm, chemotherapy was performed after obtaining her consent. She reported, "It is hard to walk, because my stomach is heavy." The weight of the mass was estimated from the size to be about 3 kg. She had a good appetite and defecation/flatus.

5-Fu 500 mg, Isovorin 250 mg, and 10A + Topotecin 40 mg were administered once a week, but there were no adverse reactions such as nausea, vomiting, diarrhea, or anorexia.

9) October 2003

The tumor partly became necrotic along the blood vessels after the start of chemotherapy, but the necrotic part disappeared and the tumor began to increase again 4 days after the completion of chemotherapy.

10) December 2003

CEA increased to 98 ng/ml. There was bleeding from the tumor. In spite of stricture with Oxytzel, Spongel, and Tacho Comb, bleeding recurred. However, anemia was not clear, and the RBC count was 3,000,000/mm³. At her request, chemotherapy was withdrawn and immunotherapy alone given. The WBC count increased to 16,900/mm³, which is possibly because of inflammation due to cancer. The chemotherapy caused no myelosuppression. The appetite slightly decreased, but no nausea or vomiting occurred. She weakened and walked with the help of a stick. The enlarged abdomen from the tumor hindered walking.
The appetite decreased and she ate only half the meals. She weakened further and often lay down. She reported, "When I walk, I always lean back because of my heavy stomach." She walked along the wall to the lavatory. Malaise was mild. She was still alive on February 17.

Discussion

SMJN originates from primary cancer in the stomach, ovary, pancreas, or other areas, and the mean remaining life expectancy is said to be 9.8 months. To the author's knowledge, between 1970 and now, there have been 12 cases of SMJN from colorectal cancer, including this patient (Table 1). Survival times are from 2 weeks to 11 months, with an average of 4.9 months, which is shorter than those for other SMJN. Our patient has survived for 2 years and 2 months since detection, and there have been no other similar cases. In comparison of survival time and the tumor size at detection, a patient with a tumor of 0.9 cm survived for 10 months (Case 5), while those with a tumor of 3 cm lived for only 2-3 months (Cases 10 and 11). However, a patient with a large tumor of 4 cm did survive for 11 months (Case 4).

Although Cases 10 and 11 had the same size tumor (3.0 × 3.7 cm) and survived for only 2-3 months, our patient has survived for 2 years or more. Based on these findings, tumor size is not related to prognosis.

The possible reasons for prolonged survival in this case are as follows:

1) As shown in Table 2, the patient treatment was based on immunotherapy, which did not impair the immunity determined as NK cell activity.

2) Chemotherapy was added, but no myelosuppression occurred.

3) BioBran for immunotherapy prevented decrease in physical strength and appetite. The patient also reported, "When I take it, I feel better."

4) Although the abdominal tumor gradually grew in size, the intraperitoneal mass was not so large, which avoided organ compression and complications such as intestinal obstruction due to direct invasion of the large and small intestines, and ascites due to peritoneal metastasis. She also had no liver, lung, brain, or bone metastasis, which occur through hematogenous dissemination.

5) BioBran produced no adverse reactions.

These may have protected the patient's QOL and prolonged her survival. From now on, she will be followed up using immunotherapy alone.
Bibliography


This paper is a translation of an article in Clinical Pharmacology and Therapy, Vol. 14/No. 3/May 2004.